Navigation Links
Adamas Pharmaceuticals presenta datos clínicos positivos para ADS-5102, un tratamiento para la disquinesia inducida por levodopa, en el Congreso Mundial del Parkinson
Date:10/2/2013

mente con la amantadina de liberación inmediata.

Acerca de la disquinesia inducida por la levodopa
La levodopa (también conocida como L-dopa) sigue siendo la norma de oro para el tratamiento de los síntomas motores debilitantes de la enfermedad de Parkinson. Un efecto secundario desafortunado del tratamiento prolongado con levodopa es la ocurrencia de disquinesia inducida por la levodopa (LID). La LID se caracteriza por movimientos involuntarios de la cabeza y el cuello, los brazos, las piernas o el tronco. Con el continuo tratamiento con levodopa, y a medida que la PD avanza, la LID puede ser severamente incapacitante y se ha asociado con una disminución de la calidad de vida de los pacientes de Parkinson(1). La LID afecta aproximadamente al 30 por ciento de los pacientes que toman levodopa(2), y es particularmente problemática entre los pacientes de la enfermedad de Parkinson de inicio precoz. Actualmente no hay medicamentos aprobados para el tratamiento de la LID.  Reducir la LID y mejorar el período de respuesta a los medicamentos sin disquinesia molesta están entre las mayores necesidades médicas sin resolver de los pacientes en el tratamiento de la enfermedad de Parkinson avanzada(3).

Acerca de Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals está dedicada a mejorar la vida de los afectados por trastornos del sistema nervioso central (SNC) optimizando los perfiles farmacocinéticos de medicamentos aprobados para crear tratamientos novedosos para su uso solamente como componentes de productos de combinación de dosis fija. La Compañía está actualmente estudiando una serie de fármacos basados en la aminoadamantana, candidatos para el tratamiento de la enfermedad de Parkinson, la enfermedad de Alzheimer y otros trastornos del SNC. El estudio EASED Fase 2/3, que investiga la ADS-5102 (amantadina HCl ER) para el tratamiento de la disquine
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
2. Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinsons Disease
3. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
4. Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence
5. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
6. Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
7. Inovio Pharmaceuticals to Participate in Immunotherapy Panel and Present at the 12th Annual BIO Investor Forum
8. Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial
9. Immune Pharmaceuticals Announces Focus on Capital Raising and Primary Listing in The United States
10. Industry Landscape Opens Doors for GeoBargain Polydex Pharmaceuticals
11. Prolong Pharmaceuticals Presents Novel Multi-Pronged Approach To Treating Sickle Cell Disease At The SCDAA Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... and SAN DIEGO , Dec. 17, ... PHG ; AEX: PHIA) and Volcano Corporation (NASDAQ: ... solutions for cardiovascular applications, today announced that they have entered ... will commence a tender offer to acquire all of the ... share, or a total equity purchase price of USD 1 ...
(Date:12/17/2014)... , Dec. 17, 2014 With ... (MRI), the MRI market is seeing new growth, ... breast MRI scans account for the majority of ... higher resolution of images, which are creating opportunities for ... (MRI) market is growing at a rate of ...
(Date:12/17/2014)... MARLBOROUGH, Mass. , Dec. 17, 2014 /PRNewswire/ ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced completion of enrollment in ... results from the 3-month observations confirmed the 1-month ... year:  Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... The AXA Research Fund closed out its first year ... than Euro 13 million to various European research institutions.The purpose ... of major risks in the world by supporting cutting edge ... Euro 100 million over five years, making it a major ...
... Research features from Mayo ClinicROCHESTER, Minn., March 23 ... of Discovery,s Edge, Mayo Clinic,s research magazine. You ... often as you wish. Reprinting is allowed with ... as your editorial policies permit: Visit http://discoverysedge.mayo.edu ...
Cached Medicine Technology:First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008 2First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008 3Discovery's Edge Spring Issue - http://discoverysedge.mayo.edu 2
(Date:12/20/2014)... 20, 2014 An improving macroeconomic landscape ... benefited the Massage Services industry over the ... industry products, the anticipated 1.0% annualized increase in per ... consumers with the means to afford additional massages. “While ... massage in a given year has declined from 2009 ...
(Date:12/20/2014)... December 20, 2014 DePuy Pinnacle ... metal-on-metal version of the artificial hip system was ... and federal courts, Bernstein Liebhard LLP reports. According ... County Superior Court on December 2nd, counsel in ... deposition of plaintiffs on November 19, 2014, with ...
(Date:12/20/2014)... 2014 (HealthDay News) -- The holidays can be anything ... with fresh trees, scented candles and other allergy triggers. ... decorations that have been packed away in dank basements ... and asthma patients," Dr. Rachna Shah, an affiliate faculty ... said in Loyola news release. Shah, who is ...
(Date:12/20/2014)... 20, 2014 The Doctor’s Office Urgent Care ... better part of a decade. They’ve treated over 40,000 ... faster healthcare alternative to the Paramus area. ... new additions to their staff of top-notch board certified physicians: ... MD. These new doctors will work tirelessly to ...
(Date:12/20/2014)... December 20, 2014 As Risperdal ... forward in U.S. courts, Bernstein Liebhard LLP notes ... that children treated with the medication may experience ... breast development and lactation. The study, which appears ... and adolescents who began treatment with risperidone, an ...
Breaking Medicine News(10 mins):Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:Holiday Trimmings Can Trigger Allergies 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4
... ... addresses the need for animal-free transferrin in many applications including Stem Cells, Primary Cells, ... ... InVitria today announced the launch of Optiferrin , a high performance, well-defined and ...
... ... offers breaking news surrounding the influenza A (H1N1) virus. The latest developments on ... ... since the outbreak, leading medical newspapers, Infectious Disease News and Infectious Diseases in Children ...
... , , , Hoffa Denounces ... WASHINGTON, Sept. 16 Teamsters General President Jim Hoffa today said the ... plans worth more than $8,000 is unfair and unnecessary. , ... would also levy the 35 percent tax for family plans worth $21,000. ...
... , , , ... Wisconsin today announced the launch of an H1N1 influenza prevention campaign ... on the importance of practicing healthy habits this cold and flu ... (K-12) about how to prevent the spread of viruses--including H1N1--as well ...
... , , MINNEAPOLIS, Sept. ... announced the first ever meeting of thought leading spine surgeons to ... SI Joint pathology, a frequent cause of low back pain. ... included Steven Garfin (former president of NASS, Chief of Orthopedics at ...
... , BARCELONA, Spain, September ... be avoided in African infants using a safe, ... malaria in Infants (IPTi),with the medicine sulphadoxine-pyrimethamine (SP), ... Results of a,meta-analysis examining six clinical trials in ...
Cached Medicine News:Health News:InVitria Successfully Completes Beta Testing and Announces Commercial Launch of Optiferrin for Mammalian Cell Culture 2Health News:Infectious Disease News and Infectious Diseases in Children Provide Online Reports Dedicated to Influenza A (H1N1) virus: 2Health News:Infectious Disease News and Infectious Diseases in Children Provide Online Reports Dedicated to Influenza A (H1N1) virus: 3Health News:Teamsters Oppose Baucus Plan to Tax Health Insurance Companies 2Health News:Children's Hospital of Wisconsin Launches H1N1 Prevention Campaign Geared Toward Children 2Health News:Children's Hospital of Wisconsin Launches H1N1 Prevention Campaign Geared Toward Children 3Health News:Academic Opinion Leaders in the Field of Spine Surgery & Sacroiliac Joint Experts Attend SI-BONE's National Summit on the Diagnosis of Sacroiliac Pathology 2Health News:Academic Opinion Leaders in the Field of Spine Surgery & Sacroiliac Joint Experts Attend SI-BONE's National Summit on the Diagnosis of Sacroiliac Pathology 3Health News:Academic Opinion Leaders in the Field of Spine Surgery & Sacroiliac Joint Experts Attend SI-BONE's National Summit on the Diagnosis of Sacroiliac Pathology 4Health News:Malaria Control Method Could Prevent 6 Million New Infant Cases 2
The MPM-1 offers a broad range of functions to attain new levels of parenchymal and ventricular monitoring through fiberoptic technology at the source....
The IVR-Optical Tracking system is engineered for easy calibration. This procedure can be done within five minutes by trained personnel, and is the only calibration required....
Slightly curved blunt dissector, double-ended. Length 11 1/2" (272 mm)...
Penfield Dissector #2...
Medicine Products: